Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in
relapsed and refractory patients with aggressive lymphoid malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania